|
---|
Category:Report
MONTHYEARML24018A1152024-01-19019 January 2024 Acu Msrr - Historic and Cultural Resources ML23338A2572023-12-14014 December 2023 Kairos Power LLC - Summary Record of Decision ML23333A0142023-11-27027 November 2023 Attachment F - Groundwater Tek Inc - Peer Review Study Final-1 ML23333A0172023-11-27027 November 2023 Attachment I - Chin - the Cooling Canal System at the FPL-Turkey-Point Power Station ML23229A2272023-11-0909 November 2023 Response to SRM-M230814 - Rulemaking - Final Rule - Comment Response Document - Emergency Preparedness for Small Modular Reactors and Other New Technologies ML23251A0462023-09-30030 September 2023 Technical Report - Review of Documents Related to Tank 12H Grout Formulations ML23194A1352023-09-0707 September 2023 OMB 3150-0007, Final Supporting Statement for 10 CFR Part 34, Licenses for Radiography and Radiation Safety Requirements for Radiographic Operations ML23192A7672023-08-21021 August 2023 Intercontinental Energy Corporation Final Completion Review Report Review and Approval ML22353A5992023-06-21021 June 2023 Enclosure - NMSS VLSSIR Wg Report and Implementation Guidance ML23097A1712023-05-0808 May 2023 Review of New and Potentially Significant Information for the Holtec Environmental Impact Statement for a Consolidated Interim Storage Facility for Spent Nuclear Fuel in Lea County, New Mexico ML22271A8622023-03-24024 March 2023 OMB-3150-0017 Final Supporting Statement for 10 CFR Part 30 Rules of General Applicability to Domestic Licensing of Byproduct Material ML22320A0752023-02-28028 February 2023 Draft Supporting Statement- Requests to Indian Tribes for Information (3150-0245) ML22318A1272023-01-0303 January 2023 Final OMB Supporting Statement: NRC Form 314 ML22133A0462022-11-10010 November 2022 Response to SRM-M220323: Final Rule-Backfitting and Issue Finality Assessment for Fitness for Duty Drug Testing Requirements ML22133A0522022-11-10010 November 2022 Response to SRM-M220323: Final Rule-Response to Public Comments for Fitness for Duty Drug Testing Requirements SECY-20-0109, Rulemaking: Regulatory Basis for Reporting Requirements for Nonemergency Events at Nuclear Power Plants Rulemaking2022-11-0404 November 2022 Rulemaking: Regulatory Basis for Reporting Requirements for Nonemergency Events at Nuclear Power Plants Rulemaking ML21267A0942022-09-30030 September 2022 Rulemaking: Final Rule: Comment Response Document: Incorporate by Reference American Society of Mechanical Engineers Boiler and Pressure Vessel Code and Operations and Maintenance Code ML21267A0982022-09-30030 September 2022 Rulemaking: Final Rule: Annotated Public Comments Document: Incorporate by Reference American Society of Mechanical Engineers Boiler and Pressure Vessel Code and Operations and Maintenance Code ML22117A2072022-08-16016 August 2022 OMB 3150-0120, Supporting Statement Draft for NRC Form 313 Application for Materials License, and NRC Forms 313A ML22165A1662022-07-20020 July 2022 OMB 3150-0055, Final Supporting Statement for Title 10 of the Code of Federal Regulations Part 75 Safeguards on Nuclear Material - Implementation ML22130A1542022-07-0707 July 2022 Final OMB Supporting Statement for 10 CFR Part 150 Exemptions and Continued Regulatory Authority in Agreement States and Offshore Waters ML22178A0662022-05-24024 May 2022 SRMC-CWDA-2022-00006, Rev. 0, Fiscal Year 2022 Savannah River Site Liquid Waste Facilities Performance Assessment Maintenance Program ML22084A6102022-04-11011 April 2022 NRC Communication with American Board of Health Physics (Abhp) in 2019 Thru 2022 ML21196A1002022-03-0202 March 2022 Rulemaking: Final Rule: Comment Response Document American Society of Mechanical Engineers Code Cases RG 1.84, Rev 39; RG 1.147, Rev 20; and RG 1.192, Rev 4 ML22032A0012022-02-28028 February 2022 Rulemaking; Proposed Rule; Unofficial Redline Rule Language for the Proposed Rule - Regulatory Improvements for Production and Utilization Facilities Transitioning to Decommissioning ML22200A2692022-02-0202 February 2022 5Q1.2-302, Rev. 31, Proceduradiation Monitoring - Water Sampling Analysis ML22021B2992022-01-21021 January 2022 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39, Release of Patients Administered Radioactive Materials, Review and Comment on the Draft Civaderm Device Licensing Guidance, Final Report, January 21, 2022 ML21350A4522021-12-15015 December 2021 Enclosure - Materials RAI Response Clarifications ML21280A1032021-12-0606 December 2021 Updated Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21341A5592021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comments on the Draft Civaderm Device Licensing Guidance, Draft Report, December 1, 2021 ML21341A5642021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comment on Draft Proposed Revision 2 to Regulatory Guide 8.39, Draft Report, December 15, ML21341A5612021-11-29029 November 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on Alpha Dart, Review and Comment on Draft Licensing Guidance Alpha Tau Alpha Dart Manual Brachytherapy, Draft Report, December 15, 2021 ML21294A3422021-11-24024 November 2021 COVID-19 Public Health Emergency Oversight Activities Assessment Phase B Report ML21172A2822021-10-19019 October 2021 Physical Security Requirements for Category II Fuel Cycle Facilities Information Sheet (HALEU Related) ML21286A8002021-10-15015 October 2021 Enclosure 1 - Request for Supplemental Information and Observation for the Model No. CR3MP Package ML21288A1262021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Final Report, October 14, 2021 ML21287A6312021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics Subcommittee, Final Report, October 14, 2021 ML22012A0702021-10-0404 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Events, Draft Report, October 4, 2021 ML21242A0592021-09-30030 September 2021 Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21259A2182021-09-22022 September 2021 Request for Supplemental Information ML22012A0652021-09-20020 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics, Draft Report, September 20, 2021 ML22012A0672021-09-0808 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Draft Report, September 8, 2021 ML21232A5432021-08-20020 August 2021 Advanced Reactors Details Website ML22004A2362021-07-31031 July 2021 CAP88 E-Plan Evaluation Final ML21210A3512021-07-30030 July 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Extravasations, Review and Comments on the Preliminary Evaluation of Radiopharmaceutical Extravasation and Medical Event Reporting, Draft Report, July 30, 2021 ML22004A2312021-07-23023 July 2021 CAP88 E-Plan Eval ML21173A0712021-07-19019 July 2021 Final Supporting Statement for 10 CFR Part 31, (3150-0016), 2021 Information Collection Renewal ML21246A1662021-07-0909 July 2021 Enclosure to Idaho State University License Renewal Application - Request for Supplemental Information ML21085A7472021-04-30030 April 2021 Glwg Agreement State Survey Summary ML21144A1202021-04-0808 April 2021 RA-432-Reclassified 2024-01-19
[Table view]Some use of "" in your query was not closed by a matching "". Category:Technical
MONTHYEARML24018A1152024-01-19019 January 2024 Acu Msrr - Historic and Cultural Resources ML23333A0142023-11-27027 November 2023 Attachment F - Groundwater Tek Inc - Peer Review Study Final-1 ML23333A0172023-11-27027 November 2023 Attachment I - Chin - the Cooling Canal System at the FPL-Turkey-Point Power Station ML23251A0462023-09-30030 September 2023 Technical Report - Review of Documents Related to Tank 12H Grout Formulations ML23192A7672023-08-21021 August 2023 Intercontinental Energy Corporation Final Completion Review Report Review and Approval ML22353A5992023-06-21021 June 2023 Enclosure - NMSS VLSSIR Wg Report and Implementation Guidance ML23097A1712023-05-0808 May 2023 Review of New and Potentially Significant Information for the Holtec Environmental Impact Statement for a Consolidated Interim Storage Facility for Spent Nuclear Fuel in Lea County, New Mexico ML22178A0662022-05-24024 May 2022 SRMC-CWDA-2022-00006, Rev. 0, Fiscal Year 2022 Savannah River Site Liquid Waste Facilities Performance Assessment Maintenance Program ML22021B2992022-01-21021 January 2022 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39, Release of Patients Administered Radioactive Materials, Review and Comment on the Draft Civaderm Device Licensing Guidance, Final Report, January 21, 2022 ML21280A1032021-12-0606 December 2021 Updated Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21341A5592021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comments on the Draft Civaderm Device Licensing Guidance, Draft Report, December 1, 2021 ML21341A5642021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comment on Draft Proposed Revision 2 to Regulatory Guide 8.39, Draft Report, December 15, ML21341A5612021-11-29029 November 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on Alpha Dart, Review and Comment on Draft Licensing Guidance Alpha Tau Alpha Dart Manual Brachytherapy, Draft Report, December 15, 2021 ML21294A3422021-11-24024 November 2021 COVID-19 Public Health Emergency Oversight Activities Assessment Phase B Report ML21172A2822021-10-19019 October 2021 Physical Security Requirements for Category II Fuel Cycle Facilities Information Sheet (HALEU Related) ML21288A1262021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Final Report, October 14, 2021 ML21287A6312021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics Subcommittee, Final Report, October 14, 2021 ML22012A0702021-10-0404 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Events, Draft Report, October 4, 2021 ML22012A0652021-09-20020 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics, Draft Report, September 20, 2021 ML22012A0672021-09-0808 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Draft Report, September 8, 2021 ML21232A5432021-08-20020 August 2021 Advanced Reactors Details Website ML21210A3512021-07-30030 July 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Extravasations, Review and Comments on the Preliminary Evaluation of Radiopharmaceutical Extravasation and Medical Event Reporting, Draft Report, July 30, 2021 ML21085A7472021-04-30030 April 2021 Glwg Agreement State Survey Summary ML21144A1192021-04-0808 April 2021 RA-136-Reclassified ML21144A1202021-04-0808 April 2021 RA-432-Reclassified ML21144A1222021-04-0808 April 2021 SYP-233-Reclassified ML20133J9292020-05-18018 May 2020 Enclosure 1, Technical Evaluation Review of Decommissioning Funding Plan (Publicly Available) ML20128J8322020-05-11011 May 2020 Technical Evaluation Report for the Draft Wir Evaluation for Closure of Wma C at Hanford Site, Washington ML20079E0862020-03-0202 March 2020 Necr B8 Wb (002) ML20079E0892020-03-0202 March 2020 Reply to Arlt Comments 3-2-2020 Draft (002) ML20075A0292020-03-0202 March 2020 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Bylaws Subcommittee, Draft Report, March 2, 2020 ML19297E7912019-10-23023 October 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on the Appropriateness of Medical Event Reporting, Final Report, October 23, 2019 ML19280D1632019-10-0606 October 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Comments on the Draft Evaluation of Training & Experience Requirements for Radiopharmaceuticals Secy Paper, Draft Report, October 6, 2019 ML19297E6942019-08-28028 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on the Appropriateness of Medical Event Reporting, Draft Report, August 28, 2019 ML19297E9022019-08-21021 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Event Reporting, Review of FY2018, Draft Report, August 21, 2019 ML19296D1202019-08-0808 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on ACMUI Institutional Memory, Draft Report, August 8, 2019 ML19106A3672019-07-25025 July 2019 Germanium-68/Gallium-68 Pharmaceutical Grade Generators Licensing Guidance ML19162A2592019-07-22022 July 2019 Technical Analyses of the Hazards of Disposal of Greater-Than-Class C (GTCC) Waste ML19198A2522019-06-20020 June 2019 Alternate Disposal Request - Rail Shipments (License DPR-28, Docket No. 50-271) ML18061A0502018-12-31031 December 2018 U.S. Nuclear Regulatory Commission Staff Responses to Public Comments on Proposed Rule: Amendments to Material Control and Accounting Regulations and Associated Draft Guidance ML18164A0712018-09-20020 September 2018 Us Ecology Idaho Site-Specific Dose Assessment Rev. 3 - TER (Public) ML18204A2142018-08-28028 August 2018 Enclosures 1-6: Pssc Multiple Closure ML18071A4132018-02-27027 February 2018 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Physical Presence Requirements for the Leksell Gamma Knife Icon, Final Report, February 27, 2018 ML18033B0332018-02-0101 February 2018 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Physical Presence Requirements for the Leksell Gamma Knife Icon, Revised Draft Report, February 1, 2018 ML17293A6262017-10-31031 October 2017 Us Sixth National Report for the Joint Convention on the Safety of Spent Fuel Management and on the Safety of Radioactive Waste Management ML17037D1152017-02-0404 February 2017 SONGS ISFSI Only PSP Amendment Nshcd Pages ML17293A2482016-09-13013 September 2016 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Comments on the Yttrium-90 Microsphere Brachytherapy Licensing Guidance, Draft Report, September 13, 2016 ML0420503102004-07-22022 July 2004 Request for Additional Information on License Application and Safety Analyses Report ML0227603052002-09-30030 September 2002 Degradation of the Davis-Besse Nuclear Power Station Reactor Pressure Vessel Head Lessons-Learned Report - Signature Page 2024-01-19
[Table view]Some use of "" in your query was not closed by a matching "". |
Text
PUBLIC VERSION TECHNICAL EVALUATION REPORT OF US ECOLOGY IDAHOS PROPOSED METHODOLOGY SUPPORTING ALTERNATE WASTE DISPOSAL PROCEDURES IN ACCORDANCE WITH 10 CFR 20.2002 INTRODUCTION US Ecology Idaho, Inc. (USEI) operates a Resource Conservation and Recovery Act (RCRA)
Subtitle C disposal facility located in Grand View, Idaho. USEI is permitted by Idahos Department of Environmental Quality (IDEQ) and is not a U.S. Nuclear Regulatory Commission (NRC) licensee. An NRC licensee or applicant for an NRC license seeking to dispose of licensed material at USEI must request approval from the NRC (or Agreement State). In addition to approving the licensees disposal request, the NRC must also exempt USEI from NRC licensing requirements (i.e., the NRC would issue an exemption under 10 CFR 30.11, 10 CFR 40.14, or 10 CFR 70.17) in order for USEI to accept the material. Upon approval of both a licensees disposal request and the USEI exemption the licensee would then be permitted to dispose of the subject licensed material at USEI.
In 2013, USEI proposed the use of a site-specific dose assessment (SSDA) methodology for calculating doses to support licensees disposal requests and USEI exemption requests for the transfer and disposal of licensed materials at USEI. On August 24, 2015, NRC staff approved the use of the USEI SSDA methodology and corresponding technical basis document (TBD),
designated as Version 1, (ML15125A364 [cover letter] and ML15125A466 [public version of TER]). In a letter dated August 4, 2017 (ML17230A221), USEI requested that the NRC staff review and approve an updated version, Version 3, of the SSDA methodology and corresponding TBD. According to USEI, these updates refine the calculations performed when evaluating future licensee disposal requests and corresponding USEI exemption requests and address some minor technical errors found in the evaluation process since the approval of Version 1.1 The NRC staff has prepared a technical evaluation report (TER) to document the NRC staffs technical review of the Version 3 SSDA methodology and associated TBD. In performing this technical review, the NRC staff evaluated the technical basis and assumptions incorporated into the USEI calculations. NRC staff also used the updated SSDA methodology to evaluate two previously approved USEI requests and compared the findings. This document is the publicly-available version of the TER; a version of the TER that contains proprietary information is not publicly available in accordance with 10 CFR 2.390(a)(4). This publicly-available version describes, on a more general level, the basis on which the NRC staff reviewed USEIs proposed Version 3 SSDA methodology and supporting TBD and summarizes the staffs findings.
Specific details related to the calculations used in the Version 3 SSDA methodology are not explained in this document.
PURPOSE 1
Version 2 of the SSDA addressed grammatical and other non-technical issues. It was never sent to the NRC for review and no technical evaluations were performed using Version 2.
PUBLIC VERSION
PUBLIC VERSION 2
The SSDA methodology is intended to streamline both the preparation of, and the NRC staffs subsequent review of, the disposal and exemption request review process by establishing bounding, risk-based performance criteria. The SSDA methodology combines the information required by NRC regulations, including project-specific information (e.g., radionuclides of concern, number of trucks transporting waste, etc.), with site-specific parameter values associated with the USEI site and the dose assessment models commonly used when considering these types of requests.
USEI is now seeking NRC staff approval of its updated SSDA methodology (Version 3).
Version 3 refines the calculations performed when evaluating doses associated with the transport and disposal of licensed material at USEI. Version 3 also corrects minor errors that were discovered since the approval of Version 1. During its review of Version 3, the NRC staff considered these corrections, updates, and modifications while confirming that these changes do not impact the overall functionality of the SSDA.
EVALUATION OF UPDATES AND REVISIONS In Version 3, USEI made numerous updates and revisions to the SSDA methodology to refine the calculations performed when evaluating doses associated with both the transport of licensed material to USEI and the disposal of that licensed material at the site. Version 3 also corrects errors that were discovered within the Version 1 calculations. The NRC staff reviewed Version 3 and has found that the changes and updates provide a more accurate description of the potential doses received by those individuals involved in the transport and disposal processes related to current USEI operations. NRC staff also evaluated a previously approved 2016 request to transport and dispose of water containing radioactive material at USEI (ML17082A581) as well as a 2009 disposal request that was used as an analysis for the evaluation of the Version 1 SSDA methodology (ML110110283). The data from these two previously approved requests were evaluated using the Version 3 SSDA methodology to ensure that the Version 3 changes did not undermine the functionality of the previously approved Version 1 SSDA methodology.
Truck Drivers and Shipping Containers The Version 3 SSDA methodology provides additional details related to the packaging and shipping processes used to transport radioactive waste to USEI. These additional details enable the SSDA to consider the doses related to the shipment of radioactive material as bulk material in dump trucks or in specific container types on the back of trailers. The Version 3 SSDA methodology also evaluates doses related to the shipment of contaminated water via tanker trucks (Version 1 of the SSDA only considered whether the material was shipped as bulk material or within a general container and did not consider the shipment of contaminated water).
Driver doses are calculated using the Microshield computer code with the driver set at a fixed distance from the waste. A shielding thickness is included to account for the type of container used and the thickness of the truck cab walls. The Version 3 SSDA methodology accounts for the variations in distances and thicknesses based on the mode of transportation and the type of container used (or if the material is shipped as bulk material). These calculations are PUBLIC VERSION
PUBLIC VERSION 3
dependent on the inputs to the SSDA. Table 1 provides a comparison of the truck driver distances and the shielding thicknesses considered for various shipment types.
Table 1. Summary of truck driver distances and shielding thicknesses for shipping various materials Material Driver Distance Shielding Bulk soil and debris 0.6 m (2 ft) 0.635 cm (0.25 inch) thick aluminum IMC shipments 4 m (13.1 ft) 0.635 cm (0.25 inch) thick aluminum Water 3.3 m (10.8 ft) .5 cm (0.197 inch) thick steel In its evaluation of the Version 3 SSDA methodology, the NRC staff compared the doses to truck drivers associated with the different shipment options. The results showed that not only do the doses received depend on the type of package used but that the maximally exposed individual (MEI) (i.e., the worker that receives the largest dose associated with the transportation and disposal process) can vary depending on the type of shipping container used.
Additional Worker Scenarios The Version 3 SSDA methodology also included additional worker scenarios related to the onsite processing of radioactive waste at USEI, such as.:
- Container Pad Operators who process the shipments of small containers (B-25 boxes, drums, etc.) upon arrival at USEI;
- Treatment Plant Truck Drivers who transport any waste that requires treatment prior to disposal in the landfill; and
- Container Pad Truck Drivers who transport the containerized waste from the container pad to the landfill.
Incorporation of these additional worker scenarios into the list of calculated doses is dependent on the inputs to the SSDA.
Analysis of Water Transport-Related Issues The Version 3 SSDA methodology added the ability to calculate doses associated with the transportation and disposal of water containing radioactive material. A review of the Version 3 calculations show that selecting water as the waste form impacts the dimensions of the truck used in the Microshield computer code calculations, the amount of time spent transporting and processing the waste, and specific parameters associated with the dose calculations for individuals involved in the transport and disposal process.
The NRC staff used a 2016 request to transport radioactively-contaminated water from the Vermont Yankee power reactor to USEI for disposal (ML17082A581) as a basis to assess the ability of the Version 3 SSDA methodology to calculate doses related to transportation and disposal activities. The 2016 NRC staff review relied upon the Version 1 SSDA methodology with conservative assumptions made to account for the fact that the Version 1 SSDA PUBLIC VERSION
PUBLIC VERSION 4
methodology did not include inputs for calculating doses associated with the transport and disposal of contaminated water. As expected, doses calculated using the water transport capabilities incorporated into Version 3 were more realistic than the doses calculated using the Version 1 methodology.
Comparison of Version 3 and Version 1 In Version 3, USEI made numerous changes and updates to the SSDA in order to refine the calculations performed when evaluating doses associated with the transport to and the disposal of licensed material at USEI. USEI also corrected errors that were discovered within the calculations since the issuance of Version 1. To ensure that these changes did not impact the doses calculated by the updated SSDA, the NRC staff evaluated the same 2009 USEI exemption request used as an independent analysis for the evaluation of Version 1 of the SSDA. This 2009 request evaluated the shipment and disposal of low-activity radioactive material from Toronto, Canada to USEI. Information provided in both the initial submittal (ML090860763) and the final SER that supported the NRC staffs approval of the exemption request (ML110110283) were used to evaluate the Version 3 SSDA. A comparison of the doses calculated using Version 1 and Version 3 of the SSDA is provided in Table 2.
Table 2. Comparison of Version 1 and Version 3 doses to workers and members of the public Exposure Scenario Version 1 Version 3 mSv/yr (mrem/yr) mSv/yr (mrem/yr)
Front-End Dray Truck Driver1 3.00E-02 (3.00E+00) 3.00E-02 (3.00E+00)
Truck Surveyors 7.35E-04 (7.35E-02) 7.35E-04 (7.35E-020 RTF Excavator Operator 2.09E-03 (2.09E-01) 1.13E-03 (1.13E-01)
Treatment Workers 3.72E-04 (3.72E-02) 3.72E-04 (3.72E-02)
Landfill Cell Operators 1.05E-03 (1.05E-01) 1.05E-03 (1.05E-01)
Post-Closure Dose 6.24E-05 (6.24E-03) 1.74E-03 (1.74E-02)
Inadvertent Intruder - Construction Scenario 9.20E-03 (9.20E-01) 9.20E-03 (9.20E-01)
Inadvertent Intruder - Well Driller Scenario 1.15E-03 (1.15E-01) 1.15E-03 (1.15E-01)
Inadvertent Intruder - Driller Occupancy 2.15E-04 (2.15E-02) 2.15E-04 (2.15E-02)
Scenario 1 MEI for both analyses CONCLUSIONS The NRC staff performed an extensive review of the Version 3 SSDA methodology as well as the updated TBD to determine whether the updates and revisions would impact the NRC staffs ability to continue using the SSDA methodology for approving the disposal of licensed material at USEI. The review involved evaluating the specific changes and updates included in Version 3 to more accurately define specific doses to individuals associated with the transport of material to and the disposal of material at USEI. Analysis of two previously approved USEI disposal requests, including a 2009 request for the disposal that was used in the evaluation of Version 1 of the SSDA, demonstrated that the Version 3 SSDA methodologys changes and PUBLIC VERSION
PUBLIC VERSION 5
updates did not impact the ability to use the SSDA to evaluate the doses received by workers involved in transport and disposal actions at USEI.
PUBLIC VERSION